CONTRACT COMPONENTS. 14.1 The following documents constitute integral components of the Funding Contract: The grant application (“Demonstration of the applicability of Hookipa’s arenaviral vector technologies for cancer immunotherapy development”) submitted via eCall in the version from 12/21/2017 General Funding Conditions for Funding Contracts as amended (version 2015) Guide for Individual Projects of Experimental Development, version 3.3 Cost Guideline 2.1 14.2 The legal bases of this Funding Contract are, in particular: The Austrian Research Promotion Agency Establishment Act (Forschungsförderungs-Strukturreformgesetz, Research Funding Structural Reform Law) as amended Union framework for State aid for research, development and innovation (Official Journal C 198 from 06/27/2014) Commission Regulation (EU) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in application of Articles 107 and 108 of the Treaty on the functioning of the European Union (TFEU 2014). Guideline for the Austrian Research Promotion Agency FFG to promote the applied research, development, and innovation (FFG Guideline for SMEs no: BMVIT-609.986/0012-111/12/2014 and BMWFW-98.310/0102-C1/10/2014)—These Guidelines were filed for exemption with the European Commission on the basis of the TFEU 2014. The Funding Recipient confirms knowledge of all contract components and fully accepts them and notes that non-compliance with the above contractual provisions may lead to the funds being reclaimed. The Funding Recipient confirms that no open reclaim order by the European Commission exists and that rescission, if any, of an incompatible funding is completed. The Funding Recipient agrees that the data listed in Art. 9(1) of the TFEU (EU Regulation No. 651/2014) Appendix III may be used to publish the information if the cash value of the grant (gross subsidy equivalent) exceeds €500,000. Vienna, 02/12/2018 /s/ Dr. ▇▇▇▇▇▇▇▇▇ Egerth-Stadlhuber /s/ ▇▇. ▇▇▇▇▇ Pseiner Dr. ▇▇▇▇▇▇▇▇▇ Egerth-Stadlhuber ▇▇. ▇▇▇▇▇ Pseiner Managing Director Managing Director Vienna, 02/27/2018 /s/ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, CFO Appendix: Guideline for the Austrian Research Promotion Agency FFG to promote the applied research, development, and innovation (FFG Guideline for SMEs) via link ▇▇▇▇▇://▇▇▇.▇▇▇.▇▇/recht-finanzen/rechtsgrundlagen General Funding Conditions for Funding Contracts as amended (version 2015) Guide for Individual Projects of Experimental Development, version 3.3 Cost Guideline 2.1 HOOIKIPA Biotech Gmbh attn ▇▇ ▇▇▇▇ ▇▇▇▇▇▇▇▇▇-Strasser ▇▇▇▇▇▇-▇▇▇▇▇▇▇▇▇▇-▇▇▇▇▇ ▇ ▇▇▇▇ ▇▇▇▇▇▇ AIP DW – 1206 Vienna, 25 October 2019 Project 865401, 857224, 850420, 849137, 844309, 836998 Dear ▇▇ ▇▇▇▇▇▇▇▇▇-▇▇▇▇▇▇▇▇, During the meeting of 23 October 2019, the Advisory Board of the FFG Basic Programmes discussed your application of 26 September to waive the reclamation of the subsidies paid out for the above-mentioned projects and approved your application under the following conditions: A) Postponement of the repayment dates as proposed in your application: - Project 836998: early repayment by 31.12.2019 in the amount of € 752,168.00 - Project 844309: early repayment by 31.03.2020 in the amount of € 1,140,021.00 - Project 857224: early repayment of 50% of the loan by 30.06.2023 in the amount of € 1,059,900.00 and repayment by 31.03.2024 in the amount of € 1,059,941.00. B) Letter of intent (as proposed) from Hookipa lnc. regarding the liabilities of Hookipa Biotech GmbH to FFG C) Guarantee of employment of at least the present number (76 employees) until at least 31.03.2024 D) Guarantee of location including operational activities until at least 31.03.2024
Appears in 1 contract
CONTRACT COMPONENTS. 14.1 The following documents constitute integral components of the Funding Contract: · The grant application (“Demonstration of the applicability of Hookipa’s arenaviral vector technologies for cancer immunotherapy development”) submitted via eCall (“Validation of a novel vector-based vaccine platform (Vaxwave) and development of an innovative vaccine against CMV”) in the version from 12/21/2017 06/20/2012. · General Funding Conditions for Funding Contracts as amended (version 20151/26/2009) · FFG General Programs Guide as amended (03/22/2012) · Cost Guideline to treating project costs in grant applications and reports for Individual Projects of Experimental Developmentprojects with grant agreements according to the FTE Guidelines and the FFG Guidelines, version 3.3 Cost Guideline 2.11.3
14.2 The legal bases of this Funding Contract are, in particular: · The Austrian Research Promotion Agency Establishment Act (Forschungsförderungs-Strukturreformgesetz, Research Funding Structural Reform Law) as amended Union framework for State aid for research, development and innovation (Official Journal C 198 from 06/27/2014) Commission Regulation (EU) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with · the internal market in application of Articles 107 and 108 of the Treaty on the functioning of the European Union (TFEU 2014). Guideline guidelines for the Austrian Research Promotion Agency FFG to promote the applied research, technology, development, and innovation (FFG Guideline for SMEs Guidelines no: BMVIT-609.986/0012BMVIT-609.986/0005-111/12/2014 111/12/2008 and BMWFW-98.310/0102BMWA-98.310/0032-C1/10/2014)—These Guidelines were filed for exemption with the European Commission on the basis of the TFEU 2014. C1/10/2008) The Funding Recipient confirms knowledge of all contract components and fully accepts them and notes them. It should be noted that non-compliance with the above contractual provisions may lead present grant offer is deemed to be withdrawn unless the funds being reclaimed. The Funding Recipient confirms that no open reclaim order by the European Commission exists and that rescission, if any, of an incompatible funding is completed. The Funding Recipient agrees that the data listed in Art. 9(1) of the TFEU (EU Regulation No. 651/2014) Appendix III may be used returns it to publish the information if the cash value of the grant (gross subsidy equivalent) exceeds €500,000FFG signed within 3 months. Vienna, 02/12/2018 07/02/2012 /s/ Dr. ▇▇▇▇▇▇▇▇▇ Egerth-Stadlhuber /s/ ▇▇. ▇▇▇▇▇ Pseiner Dr. ▇▇▇▇▇▇▇▇▇ Egerth-Stadlhuber ▇▇. ▇▇▇▇▇ Pseiner Managing Director Managing Director Vienna08/08/2012, 02/27/2018 Vienna /s/ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, CFO Appendix: Guideline Guidelines for the Austrian Research Promotion Agency FFG to promote the applied research, technology, development, and innovation (FFG Guideline for SMEsGuidelines) via link ▇▇▇▇▇://▇▇▇.▇▇▇.▇▇/recht-finanzen/content/rechtsgrundlagen foerderrichtlinien General Funding Conditions for Funding Contracts as amended (version 20151/26/2009) FFG General Programs Guide as amended (03/22/2012) Cost Guideline to treating project costs in grant applications and reports for Individual Projects of Experimental Developmentprojects with grant agreements according to the FTE Guidelines and the FFG Guidelines, version 3.3 Cost Guideline 2.1 HOOIKIPA Biotech Gmbh attn ▇▇ ▇▇▇▇ ▇▇▇▇▇▇▇▇▇-Strasser ▇▇▇▇▇▇-▇▇▇▇▇▇▇▇▇▇-▇▇▇▇▇ ▇ ▇▇▇▇ ▇▇▇▇▇▇ AIP DW – 1206 Vienna, 25 October 2019 Project 865401, 857224, 850420, 849137, 844309, 836998 Dear ▇▇ ▇▇▇▇▇▇▇▇▇-▇▇▇▇▇▇▇▇, During the meeting of 23 October 2019, the Advisory Board of the FFG Basic Programmes discussed your application of 26 September to waive the reclamation of the subsidies paid out for the above-mentioned projects and approved your application under the following conditions:
A) Postponement of the repayment dates as proposed in your application: - Project 836998: early repayment by 31.12.2019 in the amount of € 752,168.00 - Project 844309: early repayment by 31.03.2020 in the amount of € 1,140,021.00 - Project 857224: early repayment of 50% of the loan by 30.06.2023 in the amount of € 1,059,900.00 and repayment by 31.03.2024 in the amount of € 1,059,941.00.
B) Letter of intent (as proposed) from Hookipa lnc. regarding the liabilities of Hookipa Biotech GmbH to FFG
C) Guarantee of employment of at least the present number (76 employees) until at least 31.03.2024
D) Guarantee of location including operational activities until at least 31.03.20241.3
Appears in 1 contract
CONTRACT COMPONENTS. 14.1 The following documents constitute integral components of the Funding Contract: The grant application (“Demonstration of the applicability of Hookipa’s arenaviral vector technologies for cancer immunotherapy development”) submitted via eCall in the version from 12/21/2017 07/07/2016. General Funding Conditions for Funding Contracts as amended (version 2015) Guide for Individual Projects of Experimental Development, version 3.3 3.1 Cost Guideline 2.1version 2.0
14.2 The legal bases of this Funding Contract are, in particular: The Austrian Research Promotion Agency Establishment Act (Forschungsförderungs-Strukturreformgesetz, Research Funding Structural Reform Law) as amended Union framework for State aid for research, development and innovation (Official Journal C 198 from 06/27/2014) Commission Regulation (EU) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in application of Articles 107 and 108 of the Treaty on the functioning of the European Union (TFEU 2014). Guideline for the Austrian Research Promotion Agency FFG to promote the applied research, development, and innovation (FFG Guideline for SMEs no: BMVIT-609.986/0012-111/12/2014 and BMWFW-98.310/0102-C1/10/2014)—These Guidelines were filed for exemption with the European Commission on the basis of the TFEU 2014. The Funding Recipient confirms knowledge of all contract components and fully accepts them and notes that non-compliance with the above contractual provisions may lead to the funds being reclaimed. The Funding Recipient confirms that no open reclaim order by the European Commission exists and that rescission, if any, of an incompatible funding is completed. The Funding Recipient agrees that the data listed in Art. 9(1) of the TFEU (EU Regulation No. 651/2014) Appendix III may be used to publish the information if the cash value of the grant (gross subsidy equivalent) exceeds €500,000. For the Funding Agency: The Austrian Research Promotion Agency (FFG) Vienna, 02/12/2018 09/15/2016 /s/ Dr. ▇▇▇▇▇▇▇▇▇ Egerth-Stadlhuber /s/ ▇▇. ▇▇▇▇▇ Pseiner Dr. ▇▇▇▇▇▇▇▇▇ Egerth-Stadlhuber ▇▇. ▇▇▇▇▇ Pseiner Managing Director Managing Director Vienna, 02/27/2018 10/04/2016 /s/ ▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, CFO CEO Appendix: Guideline for the Austrian Research Promotion Agency FFG to promote the applied research, development, and innovation (FFG Guideline for SMEs) via link ▇▇▇▇▇://▇▇▇.▇▇▇.▇▇/recht-finanzen/rechtsgrundlagen General Funding Conditions for Funding Contracts as amended (version 2015) Guide for Individual Projects of Experimental Development, version 3.3 3.1 Cost Guideline 2.1 HOOIKIPA Biotech Gmbh attn version 2.0
1 Granting funds
1.1 On the basis of the grant application “Demonstration of the applicability of Hookipa’s arenaviral vector technologies for cancer immunotherapy development,” which was received via eCall on 09/29/2017, and on the basis of the expert decision of the advisory board in the 01/31/2018 meeting, funding will be granted for the following project: Project number: 865401 eCall number: 14249646 Pre-project no: 857224 Project name (subject-matter of Contract): Program: General Program Österreichische Tel +43 (0)5 7755 — 0 UniCredit Bank Austria AG Forschungsförderungsgesellschaft mbH Fax +43 (0)5 7755 — 97900 Account no. 10216727200, Routing no. 12000 ▇▇▇▇▇▇▇▇▇▇▇ ▇ ▇▇▇.▇▇▇.▇▇, ▇▇▇▇▇▇@▇▇▇.▇▇ IBAN ▇▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇ 1090 Vienna FH ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇-Strasser ▇ ▇▇▇▇▇▇-▇▇▇▇▇▇▇▇▇▇-▇▇▇▇▇ ▇ ▇▇▇▇ ▇▇▇▇▇▇ AIP DW – 1206 Vienna, 25 October 2019 Project 865401, 857224, 850420, 849137, 844309, 836998 Dear ▇▇ SWIFT ▇▇▇▇▇▇▇▇▇-▇▇▇▇▇▇▇▇, During the meeting of 23 October 2019, the Advisory Board of the FFG Basic Programmes discussed your application of 26 September to waive the reclamation of the subsidies paid out for the above-mentioned projects and approved your application under the following conditions:
A) Postponement of the repayment dates as proposed in your application: - Project 836998: early repayment by 31.12.2019 in the amount of € 752,168.00 - Project 844309: early repayment by 31.03.2020 in the amount of € 1,140,021.00 - Project 857224: early repayment of 50% of the loan by 30.06.2023 in the amount of € 1,059,900.00 and repayment by 31.03.2024 in the amount of € 1,059,941.00.
B) Letter of intent (as proposed) from Hookipa lnc. regarding the liabilities of Hookipa Biotech GmbH to FFG
C) Guarantee of employment of at least the present number (76 employees) until at least 31.03.2024
D) Guarantee of location including operational activities until at least 31.03.2024
Appears in 1 contract
CONTRACT COMPONENTS. 14.1 The following documents constitute integral components of the Funding Contract: · The grant application (“Demonstration of the applicability of Hookipa’s arenaviral vector technologies for cancer immunotherapy development”) submitted via eCall in the version from 12/21/2017 07/07/2016. · General Funding Conditions for Funding Contracts as amended (version 2015) · Guide for Individual Projects of Experimental Development, version 3.3 3.1 · Cost Guideline 2.1version 2.0
14.2 The legal bases of this Funding Contract are, in particular: · The Austrian Research Promotion Agency Establishment Act (Forschungsförderungs-Strukturreformgesetz, Research Funding Structural Reform Law) as amended · Union framework for State aid for research, development and innovation (Official Journal C 198 from 06/27/2014) · Commission Regulation (EU) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in application of Articles 107 and 108 of the Treaty on the functioning of the European Union (TFEU 2014). · Guideline for the Austrian Research Promotion Agency FFG to promote the applied research, development, and innovation (FFG Guideline for SMEs no: BMVIT-609.986/0012-111/12/2014 and BMWFW-98.310/0102-C1/10/2014)—These Guidelines were filed for exemption with the European Commission on the basis of the TFEU 2014. The Funding Recipient confirms knowledge of all contract components and fully accepts them and notes that non-compliance with the above contractual provisions may lead to the funds being reclaimed. The Funding Recipient confirms that no open reclaim order by the European Commission exists and that rescission, if any, of an incompatible funding is completed. The Funding Recipient agrees that the data listed in Art. 9(1) of the TFEU (EU Regulation No. 651/2014) Appendix III may be used to publish the information if the cash value of the grant (gross subsidy equivalent) exceeds €500,000. For the Funding Agency: The Austrian Research Promotion Agency (FFG) Vienna, 02/12/2018 09/15/2016 /s/ Dr. ▇▇▇▇▇▇▇▇▇ Egerth-Stadlhuber /s/ ▇▇. ▇▇▇▇▇ Pseiner Dr. ▇▇▇▇▇▇▇▇▇ Egerth-Stadlhuber ▇▇. ▇▇▇▇▇ Pseiner Managing Director Managing Director Vienna, 02/27/2018 10/04/2016 /s/ ▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, CFO CEO Appendix: Guideline for the Austrian Research Promotion Agency FFG to promote the applied research, development, and innovation (FFG Guideline for SMEs) via link ▇▇▇▇▇://▇▇▇.▇▇▇.▇▇/recht-finanzen/rechtsgrundlagen General Funding Conditions for Funding Contracts as amended (version 2015) Guide for Individual Projects of Experimental Development, version 3.3 3.1 Cost Guideline 2.1 HOOIKIPA Biotech Gmbh attn version 2.0
1 Granting funds
1.1 On the basis of the grant application “Demonstration of the applicability of Hookipa’s arenaviral vector technologies for cancer immunotherapy development,” which was received via eCall on 09/29/2017, and on the basis of the expert decision of the advisory board in the 01/31/2018 meeting, funding will be granted for the following project: Project number: 865401 eCall number: 14249646 Pre-project no: 857224 Project name (subject-matter of Contract): Program: General Program Österreichische Tel +43 (0)5 7755 — 0 UniCredit Bank Austria AG Forschungsförderungsgesellschaft mbH Fax +43 (0)5 7755 — 97900 Account no. 10216727200, Routing no. 12000 ▇▇▇▇▇▇▇▇▇▇▇ ▇ ▇▇▇.▇▇▇.▇▇, ▇▇▇▇▇▇@▇▇▇.▇▇ IBAN ▇▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇ 1090 Vienna FH ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇-Strasser ▇ ▇▇▇▇▇▇-▇▇▇▇▇▇▇▇▇▇-▇▇▇▇▇ ▇ ▇▇▇▇ ▇▇▇▇▇▇ AIP DW – 1206 Vienna, 25 October 2019 Project 865401, 857224, 850420, 849137, 844309, 836998 Dear ▇▇ SWIFT ▇▇▇▇▇▇▇▇▇-▇▇▇▇▇▇▇▇, During the meeting of 23 October 2019, the Advisory Board of the FFG Basic Programmes discussed your application of 26 September to waive the reclamation of the subsidies paid out for the above-mentioned projects and approved your application under the following conditions:
A) Postponement of the repayment dates as proposed in your application: - Project 836998: early repayment by 31.12.2019 in the amount of € 752,168.00 - Project 844309: early repayment by 31.03.2020 in the amount of € 1,140,021.00 - Project 857224: early repayment of 50% of the loan by 30.06.2023 in the amount of € 1,059,900.00 and repayment by 31.03.2024 in the amount of € 1,059,941.00.
B) Letter of intent (as proposed) from Hookipa lnc. regarding the liabilities of Hookipa Biotech GmbH to FFG
C) Guarantee of employment of at least the present number (76 employees) until at least 31.03.2024
D) Guarantee of location including operational activities until at least 31.03.2024
Appears in 1 contract
CONTRACT COMPONENTS. 14.1 The following documents constitute integral components of the Funding Contract: The · the grant application (“Demonstration Development of the applicability of innovative cancer immunotherapies based on Hookipa’s arenaviral vector technologies for cancer immunotherapy developmentVaxwave® technology”) submitted received via eCall in the version from 12/21/2017 10/01/2014 · General Funding Conditions for Funding Contracts as amended (version 20151 from 2013) · Guide for Individual Projects of Experimental Development, version 3.3 2.0 · Cost Guideline 2.1to treating project costs in grant applications and reports for projects with grant agreements according to the FTE Guidelines and the FFG Guidelines, version 1.4
14.2 The legal bases of this Funding Contract are, in particular: · The Austrian Research Promotion Agency Establishment Act (Forschungsförderungs-Strukturreformgesetz, Research Funding Structural Reform Law) as amended Union framework for State aid for research, development and innovation (Official Journal C 198 from 06/27/2014) Commission Regulation (EU) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with · the internal market in application of Articles 107 and 108 of the Treaty on the functioning of the European Union (TFEU 2014). Guideline guidelines for the Austrian Research Promotion Agency FFG to promote the applied research, technology, development, and innovation (FFG Guideline for SMEs Guidelines no: BMVIT-609.986/0012BMVIT-609.986/0005-111/12/2014 111/12/2008 and BMWFW-98.310/0102BMWA-98.310/0032-C1/10/2014)—These Guidelines were filed for exemption with C1/10/2008) The extension to 06/30/2014 was approved by the European Commission on the basis 01/30/2014. The validity of the TFEU 2014guidelines was extended until 12/31/2014 by the Federal Minister of Transport, Innovation and Technology on 03/12/2014 (No. BMVIT-609.986/0004-111/12/2014) i.e. by the Federal Minister of Science, Research and the Economy on 06/04/2014 (No. BMWFJ-98.310/0101-C1/10/2013) in accordance with the State aid regulations applicable as of 07/01/2014. The Funding Recipient confirms knowledge of all contract components and fully accepts them and notes them. It should be noted that non-compliance with the above contractual provisions may lead present grant offer is deemed to be withdrawn unless the funds being reclaimed. The Funding Recipient confirms that no open reclaim order by the European Commission exists and that rescission, if any, of an incompatible funding is completedreturns it to FFG signed within 3 months. The Funding Recipient agrees that the data listed in Art. 9(1) of the TFEU (EU Regulation No. 651/2014) Appendix III may be used to publish the information if the cash value of the grant (gross subsidy equivalent) exceeds €500,000. Vienna, 02/12/2018 /s/ Dr. ▇▇▇▇▇▇▇▇▇ Egerth-Stadlhuber /s/ ▇▇. ▇▇▇▇▇ Pseiner Dr. ▇▇▇▇▇▇▇▇▇ Egerth-Stadlhuber Stadlhuber, ▇▇. ▇▇▇▇▇ Pseiner Managing Director Managing Director Vienna, 02/27/2018 Dec. 16. 2014 /s/ ▇▇. ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇. ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, CFO CEO Appendix: Guideline Guidelines for the Austrian Research Promotion Agency FFG to promote the applied research, technology, development, and innovation (FFG Guideline for SMEsGuidelines) via link ▇▇▇▇▇://▇▇▇.▇▇▇.▇▇/recht/Allgemeine-finanzen/rechtsgrundlagen Richtlinien General Funding Conditions for Funding Contracts as amended (version 20151 from 2013) Guide for Individual Projects of Experimental Development, version 3.3 2.0 Cost Guideline 2.1 HOOIKIPA Biotech Gmbh attn ▇▇ ▇▇▇▇ ▇▇▇▇▇▇▇▇▇-Strasser ▇▇▇▇▇▇-▇▇▇▇▇▇▇▇▇▇-▇▇▇▇▇ ▇ ▇▇▇▇ ▇▇▇▇▇▇ AIP DW – 1206 Vienna, 25 October 2019 Project 865401, 857224, 850420, 849137, 844309, 836998 Dear ▇▇ ▇▇▇▇▇▇▇▇▇-▇▇▇▇▇▇▇▇, During to treating project costs in grant applications and reports for projects with grant agreements according to the meeting of 23 October 2019, the Advisory Board of FTE Guidelines and the FFG Basic Programmes discussed your application of 26 September to waive the reclamation of the subsidies paid out for the above-mentioned projects and approved your application under the following conditions:
A) Postponement of the repayment dates as proposed in your application: - Project 836998: early repayment by 31.12.2019 in the amount of € 752,168.00 - Project 844309: early repayment by 31.03.2020 in the amount of € 1,140,021.00 - Project 857224: early repayment of 50% of the loan by 30.06.2023 in the amount of € 1,059,900.00 and repayment by 31.03.2024 in the amount of € 1,059,941.00.
B) Letter of intent (as proposed) from Hookipa lnc. regarding the liabilities of Hookipa Biotech GmbH to FFG
C) Guarantee of employment of at least the present number (76 employees) until at least 31.03.2024
D) Guarantee of location including operational activities until at least 31.03.2024Guidelines, version 1.4
Appears in 1 contract
CONTRACT COMPONENTS. 14.1 The following documents constitute integral components of the Funding Contract: · The grant application (“Demonstration of the applicability of Hookipa’s arenaviral vector technologies for cancer immunotherapy development”) submitted via eCall (“Validation of a novel vector-based vaccine platform (Vaxwave) and development of an innovative vaccine against CMV”) in the version from 12/21/2017 10/30/2013. · General Funding Conditions for Funding Contracts as amended (version 20151 from 2013) · FFG General Programs Guide as amended (03/22/2012) · Cost Guideline to treating project costs in grant applications and reports for Individual Projects of Experimental Developmentprojects with grant agreements according to the FTE Guidelines and the FFG Guidelines, version 3.3 Cost Guideline 2.11.3
14.2 The legal bases of this Funding Contract are, in particular: · The Austrian Research Promotion Agency Establishment Act (Forschungsförderungs-Strukturreformgesetz, Research Funding Structural Reform Law) as amended Union framework for State aid for research, development and innovation (Official Journal C 198 from 06/27/2014) Commission Regulation (EU) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with · the internal market in application of Articles 107 and 108 of the Treaty on the functioning of the European Union (TFEU 2014). Guideline guidelines for the Austrian Research Promotion Agency FFG to promote the applied research, technology, development, and innovation (FFG Guideline for SMEs Guidelines no: BMVIT-609.986/0012BMVIT-609.986/0005-111/12/2014 111/12/ 2008 and BMWFW-98.310/0102BMWA-98.310/0032-C1/10/2014)—These Guidelines were filed for exemption with the European Commission on the basis of the TFEU 2014. C1/10/ 2008) The Funding Recipient confirms knowledge of all contract components and fully accepts them and notes them. It should be noted that non-compliance with the above contractual provisions may lead present grant offer is deemed to be withdrawn unless the funds being reclaimed. The Funding Recipient confirms that no open reclaim order by the European Commission exists and that rescission, if any, of an incompatible funding is completed. The Funding Recipient agrees that the data listed in Art. 9(1) of the TFEU (EU Regulation No. 651/2014) Appendix III may be used returns it to publish the information if the cash value of the grant (gross subsidy equivalent) exceeds €500,000FFG signed within 3 months. Vienna, 02/12/2018 12/06/2013 /s/ Dr. ▇▇▇▇▇▇▇▇▇ Egerth-Stadlhuber /s/ ▇▇. ▇▇▇▇▇ Pseiner Dr. ▇▇▇▇▇▇▇▇▇ Egerth-Stadlhuber Stadlhuber, ▇▇. ▇▇▇▇▇ Pseiner Managing Director Managing Director Vienna, 02/27/2018 on Dec. 17 2013 /s/ ▇▇. ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇. ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, CFO CEO Appendix: Guideline Guidelines for the Austrian Research Promotion Agency FFG to promote the applied research, technology, development, and innovation (FFG Guideline for SMEsGuidelines) via link ▇▇▇▇▇://▇▇▇.▇▇▇.▇▇/recht/Allgemeine-finanzen/rechtsgrundlagen Richtlinien General Funding Conditions for Funding Contracts as amended (version 20151 from 2013) FFG General Programs Guide as amended (03/22/2012) Cost Guideline to treating project costs in grant applications and reports for Individual Projects of Experimental Developmentprojects with grant agreements according to the FTE Guidelines and the FFG Guidelines, version 3.3 Cost Guideline 2.1 HOOIKIPA Biotech Gmbh attn ▇▇ ▇▇▇▇ ▇▇▇▇▇▇▇▇▇-Strasser ▇▇▇▇▇▇-▇▇▇▇▇▇▇▇▇▇-▇▇▇▇▇ ▇ ▇▇▇▇ ▇▇▇▇▇▇ AIP DW – 1206 Vienna, 25 October 2019 Project 865401, 857224, 850420, 849137, 844309, 836998 Dear ▇▇ ▇▇▇▇▇▇▇▇▇-▇▇▇▇▇▇▇▇, During the meeting of 23 October 2019, the Advisory Board of the FFG Basic Programmes discussed your application of 26 September to waive the reclamation of the subsidies paid out for the above-mentioned projects and approved your application under the following conditions:
A) Postponement of the repayment dates as proposed in your application: - Project 836998: early repayment by 31.12.2019 in the amount of € 752,168.00 - Project 844309: early repayment by 31.03.2020 in the amount of € 1,140,021.00 - Project 857224: early repayment of 50% of the loan by 30.06.2023 in the amount of € 1,059,900.00 and repayment by 31.03.2024 in the amount of € 1,059,941.00.
B) Letter of intent (as proposed) from Hookipa lnc. regarding the liabilities of Hookipa Biotech GmbH to FFG
C) Guarantee of employment of at least the present number (76 employees) until at least 31.03.2024
D) Guarantee of location including operational activities until at least 31.03.20241.3
Appears in 1 contract